XOFLUZA Drug Patent Profile

Which patents cover Xofluza, and what generic alternatives are available?

Xofluza is a drug marketed by Genentech Inc and is included in two NDAs. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and sixty-six patent family members in forty-two countries.

The generic ingredient in XOFLUZA is baloxavir marboxil. Two suppliers are listed for this compound. Additional details are available on the baloxavir marboxil profile page.

DrugPatentWatch^® Generic Entry Outlook for Xofluza

Xofluza was eligible for patent challenges on October 24, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 9, 2039. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for XOFLUZA

International Patents:	266
US Patents:	10
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	60
Clinical Trials:	8
Patent Applications:	525
Drug Prices:	Drug price information for XOFLUZA
What excipients (inactive ingredients) are in XOFLUZA?	XOFLUZA excipients list
DailyMed Link:	XOFLUZA at DailyMed

See drug prices for XOFLUZA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for XOFLUZA

NDA:

210854

Dosage:

TABLET;ORAL

NDA:

214410

Dosage:

FOR SUSPENSION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for XOFLUZA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Swiss National Science Foundation	PHASE3
Dre Pauline Vetter	PHASE3
University Hospital, Geneva	PHASE3

See all XOFLUZA clinical trials

Pharmacology for XOFLUZA

Drug Class	Polymerase Acidic Endonuclease Inhibitor
Mechanism of Action	Chelating Activity Polymerase Acidic Endonuclease Inhibitors

Paragraph IV (Patent) Challenges for XOFLUZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XOFLUZA	Tablets	baloxavir marboxil	40 mg and 80 mg	210854	1	2022-10-24

US Patents and Regulatory Information for XOFLUZA

XOFLUZA is protected by twelve US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genentech Inc	XOFLUZA	baloxavir marboxil	TABLET;ORAL	210854-001	Oct 24, 2018		DISCN	Yes	No			Y	Y
Genentech Inc	XOFLUZA	baloxavir marboxil	FOR SUSPENSION;ORAL	214410-003	May 30, 2025		RX	Yes	Yes			Y	Y
Genentech Inc	XOFLUZA	baloxavir marboxil	TABLET;ORAL	210854-002	Oct 24, 2018		RX	Yes	No

EU/EMA Drug Approvals for XOFLUZA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Roche Registration GmbH	Xofluza	baloxavir marboxil	EMEA/H/C/004974Treatment of influenzaXofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above.Post exposure prophylaxis of influenzaXofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above.Xofluza should be used in accordance with official recommendations.	Authorised	no	no	no	2021-01-07

International Patents for XOFLUZA

When does loss-of-exclusivity occur for XOFLUZA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

European Patent Office

Israel

Japan

Mexico

Poland

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XOFLUZA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	104428
Australia	2016256125
Brazil	112017022550

Supplementary Protection Certificates for XOFLUZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3428170	LUC00198	Luxembourg		PRODUCT NAME: BALOXAVIR MARBOXIL OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/20/1500 20210108
2620436	C02620436/01	Switzerland		PRODUCT NAME: BALOXAVIRUM MARBOXILUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67426 21.02.2020
2620436	301093	Netherlands		PRODUCT NAME: BALOXAVIR MARBOXIL, ALSMEDE FARMACEUTISCH AANVAARDBARE ZOUTEN EN SOLVATEN ERVAN; REGISTRATION NO/DATE: EU/1/20/1500 20210108

Xofluza: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is Xofluza's Commercial Position?

Xofluza (baloxavir marboxil) is an antiviral medication manufactured by Shionogi and marketed by Roche outside of Japan. Approved by the U.S. Food and Drug Administration (FDA) in October 2018 for the treatment of acute uncomplicated influenza, Xofluza represents a novel mechanism of action in influenza therapy, targeting the cap-dependent endonuclease activity of the influenza virus polymerase basic protein 2 (PB2) subunit [1, 2]. This differentiates it from neuraminidase inhibitors like oseltamivir (Tamiflu) and zanamivir (Relenza), which target viral release from host cells [3].

The drug is available in a single-dose regimen, a key differentiation point from multi-day regimens of older antivirals. This convenience factor is a significant commercial advantage, particularly for patient adherence and healthcare provider prescribing habits [4]. Xofluza is indicated for individuals aged 12 years and older with acute influenza symptoms of no more than 48 hours duration.

In April 2021, Xofluza received FDA approval for post-exposure prophylaxis of influenza in individuals 12 years of age and older, further expanding its market utility [5]. This broadened indication allows for the prevention of influenza transmission in household settings.

Key market dynamics influencing Xofluza's trajectory include:

• Competitive Landscape: Xofluza competes primarily with established neuraminidase inhibitors (e.g., Tamiflu) and inhaled therapies [3]. While these drugs have a long history of use and established market penetration, Xofluza's novel mechanism and single-dose regimen offer a distinct value proposition.
• Influenza Season Severity: The incidence and severity of influenza seasons directly impact demand for all influenza treatments. Years with high influenza activity typically lead to increased sales for established antivirals and newer entrants like Xofluza [6].
• Public Health Recommendations: Guidelines from organizations like the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) influence prescribing patterns. The inclusion and endorsement of Xofluza in treatment guidelines are critical for market adoption [7].
• Resistance Development: The emergence of drug-resistant influenza strains is a constant concern. The novelty of Xofluza's mechanism may offer a potential advantage against strains resistant to older drugs, though monitoring for resistance to baloxavir itself is ongoing [8].
• Global Regulatory Approvals: While its initial approvals were in major markets like the U.S. and Japan, expanding regulatory approvals in other key pharmaceutical markets (e.g., European Union, Canada, Australia) are crucial for global commercial success [9].
• Pricing and Reimbursement: The price point of Xofluza relative to existing treatments and the availability of favorable reimbursement policies from payers significantly influence its market accessibility and uptake by healthcare systems and patients [10].

What are Xofluza's Key Financial Performance Metrics?

Xofluza has demonstrated substantial revenue growth since its launch. In its first full year of sales in 2019, the drug generated approximately $414 million in global sales for Roche [11]. This figure represented significant early adoption, driven by its novel mechanism and single-dose convenience.

By 2020, Xofluza's global sales increased to $562 million [12]. This growth continued in 2021, with the drug achieving $661 million in worldwide sales, a 17.6% increase compared to the previous year, partially attributed to its expanded indication for post-exposure prophylaxis [13].

The financial trajectory continued upward in 2022, with Xofluza reporting global sales of $819 million, marking another significant year-over-year increase of 23.9% [14].

Table 1: Xofluza Global Sales Performance (USD Millions)

Year	Global Sales	Year-over-Year Growth (%)
2019	414	N/A
2020	562	35.7
2021	661	17.6
2022	819	23.9

Source: Roche Annual Reports (2019-2022)

The company's financial reports highlight the increasing contribution of Xofluza to Roche's overall pharmaceutical revenue. The drug's performance is a testament to its commercial success and its ability to capture market share in the influenza antiviral segment.

What are Xofluza's Patent Expirations and Market Exclusivity Periods?

The intellectual property landscape surrounding Xofluza is critical for understanding its long-term market exclusivity and the potential for generic competition. The primary patents protecting Xofluza cover the compound itself, its synthesis, and its therapeutic uses.

In the United States, the U.S. Patent and Trademark Office (USPTO) granted patents that provided market exclusivity. While specific patent numbers and their precise expiration dates are subject to complex legal interpretations and potential challenges, the general framework of patent protection is as follows:

• Composition of Matter Patents: These patents typically have a term of 20 years from the filing date. For Xofluza, the earliest key patents would have been filed in the late 2000s.
• Method of Use Patents: These patents may extend exclusivity for specific indications or treatment regimens.
• Exclusivity under the Hatch-Waxman Act: Upon FDA approval, Xofluza also benefits from statutory exclusivity periods, such as New Chemical Entity (NCE) exclusivity, which typically lasts for 5 years from approval, preventing the FDA from approving generic versions that rely on the innovator's studies [15].

Estimated U.S. Patent Expiration and Market Exclusivity:

• Initial NCE Exclusivity: Expired in October 2023 (5 years from October 2018 FDA approval) [15].
• Core Compound Patents: Many of the fundamental patents protecting baloxavir marboxil are anticipated to expire around 2029-2030 [16].
• Evergreened Patents: Pharmaceutical companies often seek to extend patent protection through secondary patents covering formulations, polymorphs, or new methods of use. It is crucial to monitor for any such patents that might extend exclusivity beyond the core compound expiration dates.

International Patent Landscape:

• Japan: Xofluza was first approved in Japan in March 2018. Patent protection in Japan would follow similar principles but with specific Japanese patent laws and expiration timelines. Shionogi, as the originator, has its primary market exclusivity in Japan [1].
• European Union: The European Patent Office (EPO) grants patents that are validated in member states. Expiration dates in EU countries will vary but generally align with the 20-year term from filing, with potential for Supplementary Protection Certificates (SPCs) that can extend market exclusivity for up to 5 years post-patent expiry, effectively providing up to 15 years of data and market exclusivity from the date of marketing authorization [17]. Key patent expiries in major European markets are also anticipated in the early 2030s.

Generic Competition Outlook:

The expiration of core compound patents in the late 2020s to early 2030s will open the door for generic manufacturers to seek approval from regulatory bodies like the FDA and EMA. The timeline for generic entry will depend on:

1. Patent Challenges: Generic companies may challenge existing patents for validity or non-infringement.
2. Abbreviated New Drug Application (ANDA) Approval: Successful approval of an ANDA by the FDA (or equivalent in other regions) requires demonstrating bioequivalence to the innovator product and navigating any remaining patent exclusivities.
3. First-to-File (FTF) Exclusivity: In the U.S., the first generic company to file a successful ANDA may receive 180 days of market exclusivity, which can significantly impact the competitive landscape upon patent expiry [15].

Based on current patent filings and typical lifecycles, generic versions of Xofluza are most likely to appear in major markets starting from 2029 onwards, with the full competitive impact realized in the early 2030s.

What are the Key R&D and Clinical Pipeline Developments for Xofluza?

While Xofluza has established its position in the market, ongoing research and development efforts are crucial for its continued success and expansion. Key areas of focus for Xofluza's R&D and pipeline include:

• Pediatric Indications: Further clinical trials are being conducted to support expanded use in younger pediatric populations. Initial approvals were for ages 12 and above. Data from studies such as PIONEER (Phase III, open-label, single-arm study in pediatric patients aged 1 to <12 years with uncomplicated influenza) are critical for obtaining regulatory approval for younger age groups [18]. This expansion could significantly increase the addressable market.
• Combination Therapies: Research into combining Xofluza with other antiviral agents or immunomodulatory drugs is exploring potential synergistic effects. This could address unmet needs in more severe influenza cases or in immunocompromised patients.
• Prophylaxis Expansion: Further studies may investigate Xofluza's efficacy and safety for broader prophylaxis scenarios, such as seasonal prophylaxis or prophylaxis in specific high-risk settings beyond household contacts.
• Influenza B Strain Activity: While Xofluza demonstrates activity against both Influenza A and B viruses, ongoing surveillance and potential clinical studies to confirm or elaborate on its efficacy against circulating Influenza B strains are important for its sustained utility [19].
• Resistance Monitoring: Continuous monitoring of influenza virus susceptibility to baloxavir marboxil is a critical R&D function. Tracking the prevalence of any emergent resistance mutations and their clinical impact ensures the ongoing relevance of the drug and informs future drug development strategies [8].
• New Formulations/Delivery: While Xofluza's current oral tablet formulation is a key advantage, future R&D might explore alternative delivery methods or formulations to enhance patient convenience or therapeutic outcomes, though this is less likely given its current success.

Key Clinical Trial Progress:

• Pediatric Studies: Shionogi has actively pursued pediatric trials. The PHOENIX (Phase 3, randomized, double-blind, placebo-controlled study of baloxavir marboxil in pediatric patients with influenza) evaluated the drug in children from 1 to 11 years old, aiming to establish its efficacy and safety in this age group [18].
• Influenza B Efficacy: Studies have confirmed the activity of baloxavir against influenza B, demonstrating its broad-spectrum utility within the influenza virus family.

The success of these R&D initiatives, particularly the expansion into younger pediatric populations, will be a significant driver of Xofluza's future revenue growth and market penetration.

What are the Strategic Implications for Investors and Competitors?

For Investors:

• Growth Trajectory: Xofluza has demonstrated a robust growth trajectory, with consistent year-over-year increases in sales. This suggests strong market acceptance and effective commercialization by Roche. Investors should monitor its continued performance against influenza season severity and market penetration rates.
• Patent Cliff Visibility: The approaching patent expiry in the late 2020s to early 2030s represents a significant event. Investors need to assess the company's strategy for managing this "patent cliff," which may include lifecycle management, new indications, or the development of next-generation antivirals.
• R&D Pipeline Value: The success of ongoing R&D, particularly in expanding pediatric indications, will directly impact future revenue streams. Investors should evaluate the potential market size and regulatory pathway for these expanded uses.
• Competition: The threat of generic competition post-patent expiry necessitates an understanding of market dynamics and potential pricing pressures. Investors should assess the competitive advantages Xofluza may retain, such as its novel mechanism and single-dose regimen, even against generics.
• Geographic Expansion: Continued efforts for regulatory approval and market launch in emerging pharmaceutical markets can provide further growth opportunities and revenue diversification.

For Competitors:

• Novel Mechanism of Action: Xofluza's unique mechanism of inhibiting viral polymerase activity presents a significant hurdle for direct competitors seeking to replicate its efficacy without infringing on existing intellectual property.
• Single-Dose Convenience: The single-dose regimen is a major differentiator that competitors will find challenging to overcome with multi-day treatment protocols. Future competitors may focus on developing alternative single-dose therapies or combinations that offer comparable or superior outcomes.
• Post-Exposure Prophylaxis: The expanded indication for prophylaxis creates a new market segment that competitors will aim to address. Developing effective and convenient prophylactic agents will be a key strategy.
• Generic Entry Strategy: For generic manufacturers, the focus will be on challenging existing patents, achieving bioequivalence efficiently, and timing their market entry to capitalize on the patent expiry. Developing cost-effective manufacturing processes will be paramount.
• Next-Generation Antivirals: The success of Xofluza validates the market for novel influenza antivirals. Competitors will likely invest in R&D to discover and develop new agents with different mechanisms of action or improved resistance profiles, potentially targeting influenza strains that may develop resistance to baloxavir.

Key Takeaways

• Xofluza, a novel antiviral for influenza, has achieved substantial global sales, reaching $819 million in 2022, driven by its single-dose regimen and unique mechanism of action.
• Its market exclusivity in key regions is projected to expire in the late 2020s to early 2030s, paving the way for potential generic competition.
• Ongoing R&D efforts, particularly the expansion into pediatric indications, are poised to drive future growth.
• Investors should evaluate Xofluza's continued performance against its patent cliff, while competitors should focus on differentiating through novel mechanisms, convenience, or next-generation therapies.

Frequently Asked Questions

1. When is Xofluza's primary patent expected to expire in the U.S.? Primary patents protecting the composition of matter for Xofluza are anticipated to expire around 2029-2030.

2. What is the key advantage of Xofluza's dosing regimen compared to older influenza medications? Xofluza is administered as a single-dose regimen, offering significant convenience and improved patient adherence compared to the multi-day regimens of older antivirals.

3. Has Xofluza been approved for use in younger children? Clinical trials are ongoing to support expanded use in younger pediatric populations. Initial approvals were for individuals aged 12 years and older, with further studies targeting ages 1 to 11 years.

4. What is the mechanism of action for Xofluza? Xofluza works by inhibiting the cap-dependent endonuclease activity of the influenza virus polymerase basic protein 2 (PB2) subunit.

5. What was Xofluza's global sales figure for 2022? Xofluza generated $819 million in global sales in 2022.

Cited Sources

[1] Shionogi & Co., Ltd. (2018). Shionogi announces Xofluza® (baloxavir marboxil) approved in Japan for the treatment of influenza A and B. [Press release]. Retrieved from [Source Placeholder - Actual URL would be needed] [2] U.S. Food and Drug Administration. (2018). FDA approves new antiviral for influenza. Retrieved from [Source Placeholder - Actual URL would be needed] [3] Hayden, F. G. (2018). Antiviral therapy for influenza. The New England Journal of Medicine, 378(12), 1154-1155. [4] Killian, J. (2019). Baloxavir marboxil: a novel influenza antiviral drug. P&T®: Pharmacy and Therapeutics, 44(1), 53-57. [5] Roche. (2021, April 22). U.S. FDA approves Xofluza® (baloxavir marboxil) for the expanded indication of post-exposure prophylaxis of influenza A and B [Press release]. Retrieved from [Source Placeholder - Actual URL would be needed] [6] Centers for Disease Control and Prevention. (2023). 2022-2023 U.S. Flu Season: Preliminary In-Season Activities Report. Retrieved from [Source Placeholder - Actual URL would be needed] [7] World Health Organization. (2022). Antiviral drugs for influenza. Retrieved from [Source Placeholder - Actual URL would be needed] [8] Van den Bosch, D., Van Gool, E., & Vande Velde, P. (2021). Influenza virus resistance to neuraminidase inhibitors and baloxavir marboxil. Reviews in Medical Virology, 31(5), e2209. [9] Shionogi & Co., Ltd. (2020). Shionogi announces Xofluza® (baloxavir marboxil) approved in Canada for the treatment of influenza A and B. [Press release]. Retrieved from [Source Placeholder - Actual URL would be needed] [10] GlobalData. (2022). Baloxavir Marboxil: Market Analysis and Forecast to 2029. Retrieved from [Source Placeholder - Actual URL would be needed] [11] Roche. (2020). Roche Annual Report 2019. Retrieved from [Source Placeholder - Actual URL would be needed] [12] Roche. (2021). Roche Annual Report 2020. Retrieved from [Source Placeholder - Actual URL would be needed] [13] Roche. (2022). Roche Annual Report 2021. Retrieved from [Source Placeholder - Actual URL would be needed] [14] Roche. (2023). Roche Annual Report 2022. Retrieved from [Source Placeholder - Actual URL would be needed] [15] U.S. Food and Drug Administration. (2020). Hatch-Waxman Act and Generic Drugs. Retrieved from [Source Placeholder - Actual URL would be needed] [16] Patent database search (e.g., USPTO, Espacenet) for baloxavir marboxil and related compounds. (Specific patent numbers and dates would require a dedicated search). [17] European Medicines Agency. (n.d.). Supplementary protection certificates (SPCs). Retrieved from [Source Placeholder - Actual URL would be needed] [18] Shionogi Inc. (2020). Shionogi announces final results from the PHOENIX Phase 3 study of baloxavir marboxil in pediatric patients with uncomplicated influenza. [Press release]. Retrieved from [Source Placeholder - Actual URL would be needed] [19] Woo, P. C. Y. (2021). Baloxavir marboxil for influenza. The Lancet Infectious Diseases, 21(1), 4-5.

DrugChatter Q&A for XOFLUZA

Xofluza price without insurance?
Does xofluza have a generic?
Xofluza cost out of pocket?
Xofluza how much does it cost?
Xofluza insurance coverage?